Verastem reported $181.68M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Curis USD 10.14M 10.14M Jun/2025
Cytokinetics USD 255.27M 125.43M Jun/2026
Gilead Sciences USD 7.63B 64M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
Laboratory Of America USD 141.8M 839.3M Jun/2026
Novartis USD 7.62B 739M Jun/2026
Pfizer USD 976M 727M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
TG Therapeutics USD 612.25M 170.04M Jun/2026
Verastem USD 181.68M 23.31M Mar/2026